Myriad Genetics : Statement of Changes in Beneficial Ownership – Form 4








property filing

FORM 4

Check this box if the Section 16, Form 4, or Form 5 obligations may survive. See Statement 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES BENEFICIAL OWNERSHIP STATEMENT Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average load in hours per response…0.5

1. Name and address of the reporting person *

Verratti Mark

2. Issuer name and ticker or trading symbol
MYRIAD GENETICS INC [MYGN]

5. Relationship of the reporting person(s) to the issuer
(check all that apply)

_____ Director

_____ 10% owner

_____ Officer (insert title below)

_____ Other (specify below)

Commercial Manager /

(Last)

(First)

(Center)

320 WAKARA WAY

3. Date of earliest transaction (month/day/year)

(Street)

SALT LAKE CITY

subtitles

84108

4. If modified, original submission date (month/day/year)

6. Individual or join/group registration (Check the applicable line)
_X_ Form submitted by a reporter
___ Form submitted by more than one reporter

Table I – Non-Derivative Securities Purchased, Sold or Beneficially Owned

1. Securities

2. Transaction Date (Month/Day/Year)

2A Expected execution date, if any (month/day/year)

3. Transaction Code

4. Securities purchased (A) or sold (D)

5. Number of securities beneficially owned by reported transactions

6. Form of ownership: direct (D) or indirect (I)

7. Nature of Indirect Beneficial Ownership

code

v

Crowd

(A) or (D)

Price

Table II – Beneficial Ownership of Derivative Securities (egputs, calls, warrants, options, convertible securities)
(egputs, calls, warrants, options, convertible securities)

1. Name of derivative security

2. Conversion or exercise price of the derivative security

3. Transaction Date (Month/Day/Year)

3A Expected execution date, if any (month/day/year)

4. Transaction Code

5. Number of derivative securities purchased (A) or sold (D)

6. Exercise Date and Expiry Date

7. Title and Amount of Underlying Securities Derivative Security

8. Price of the Derivative Security

9. Number of derivative securities beneficially owned by reported transaction(s)

10. Form of ownership of the derivative security: Direct (D) or Indirect (I)

11. Nature of Indirect Beneficial Ownership

code

v

(A)

(D)

Exercisable Date

Expiry Date

title

Amount or number of shares

Report owner

Name/address of reporting owner Relationships

director

10% owner

officer

Miscellaneous

Verratti Mark
320 WAKARA WAY

SALT LAKE CITY, UT84108

Chief Commercial Officer

signatures

By: Justin Hunter For: Mark Verratti

2022-09-22

**Signature of the reporting person

date

Explanation of the answers:

If the form is submitted by more than one reporter, see

Statement 5(b)(v).

(**) Deliberate misrepresentation or omission of facts is a federal offense. See

18 USC 1001 and 15 USC 78ff(a).

(1)

Represents shares retained by the company to satisfy withholding tax obligations related to the transfer of restricted stock units granted to the reporting person. The number of Myriad common shares retained was determined based on the closing price of Myriad common shares on September 21, 2022. Note: Submit three copies of this form, one of which requires a manual signature. If there is not enough space See

Procedural Statement 6 Prospects who are required to respond to the collection of information contained in this form need not respond unless the form includes a currently valid OMB number.

Disclaimer Myriad Genetics Inc. published this content on September 22, 2022 and is solely responsible for the information contained therein. Distributed by the public, unedited and unmodified, on22 Sep 2022 20:49:21 UTC

.

Public now 2022

All news about MYRIAD GENETICS, INC.

Analyst Recommendations on MYRIAD GENETICS, INC.

Sale 2022
694 m
Net Income 2022
-20.0 million
Net liquidity 2022
257 million
P/E 2022
-51.7x Yield 2022
capitalization
1 543 million
1 543 million
EV / Sale 2022
1.85x EV / Sale 2023
1.63x number of employees
2 400 free float

98.0%

Diagram MYRIAD GENETICS, INC.









Myriad Genetics, Inc. Technical Analysis Chart |  MarketScreener

Myriad Genetics, Inc. Technical Analysis Chart | MarketScreener

Technical Analysis Trends MYRIAD GENETICS, INC.

Short term medium term
long term tendencies bearish Neutral

Neutral


Please enable JavaScript in your browser settings to use dynamic charts.

To sell

Obtain Medium consensus
UNDERPERFORMANCE Number of Analysts
8th Last closing price
$19.14 Average target price
$24.93 Spread / Average Target

Please enable JavaScript in your browser settings to use dynamic charts.





Source link

READ:  2022-09-23 | NDAQ:FLGT | Press Release